 |
JOURNAL TOOLS |
| eTOC |
| Per abbonarsi |
| Sottometti un articolo |
| Segnala alla tua biblioteca |
ARTICLE TOOLS |
| Estratti |
| Permessi |
| Per citare questo articolo |
I TUOI DATI
I TUOI ORDINI
CESTINO ACQUISTI
N. prodotti: 0
Totale ordine: € 0,00
COME ORDINARE
I TUOI ABBONAMENTI
I TUOI ARTICOLI
I TUOI EBOOK
COUPON
ACCESSIBILITÀ
REVIEWS
Minerva Medica 2016 April;107(2):114-22
Copyright © 2016 EDIZIONI MINERVA MEDICA
lingua: Inglese
Fentanyl citrate sublingual formulation (Vellofent®) for quick BTcP hindering
Patrizia ROMUALDI, Sanzio CANDELETTI ✉
Department of Pharmacy and Biotechnology, Alma Mater Studiorum, University of Bologna, Bologna, Italy
The management of cancer pain presents manifold challenges: even though background pain is adequately controlled, patients frequently experience episodes of acute pain exacerbation known as breakthrough cancer pain (BTcP). The characteristics of BTcP are a rapid onset, a short duration, and a severe intensity. An innovative sublingual fentanyl citrate formulation (Vellofent®) has been developed to target BTcP. The new formulation allows to increase the solubility of fentanyl and to provide optimal oromucosal conditions for rapid drug absorption, thus featuring a shorter time to onset of pain relief (from 6 minutes post-administration).